Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Bimagrumab

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Eli Lilly · Phase 2 · Completed · Enrollment 507

NCT05616013

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Placebo/30 mg/kg Bimagrumab9 participants1 participants10 participantsn/r0
10/30 mg/kg Bimagrumab15 participants5 participants27 participantsn/r0
30 mg/kg Bimagrumab20 participants7 participants25 participantsn/r0
Placebo + 1.0 mg Semaglutide25 participants6 participants19 participantsn/r0
Placebo + 2.4 mg Semaglutide26 participants10 participants21 participantsn/r0
10 mg/kg Bimagrumab + 1.0 mg Semaglutide23 participants6 participants27 participantsn/r0
10 mg/kg Bimagrumab + 2.4 mg Semaglutide34 participants10 participants29 participantsn/r0
30 mg/kg Bimagrumab + 1.0 mg Semaglutiden/rn/rn/rn/rn/r
30 mg/kg Bimagrumab + 2.4 mg Semaglutiden/rn/rn/rn/rn/r

A count stays a count. This page does not turn a count into a percent.